In:
Liver Transplantation, Ovid Technologies (Wolters Kluwer Health), Vol. 22, No. 5 ( 2016-05), p. 644-655
Abstract:
Steatosis occurs frequently after liver transplantation (LT). We aimed to determine the prevalence of steatosis in adult LT recipients, to determine the effects of significant ( 〉 33%; grades 2‐3) steatosis on patient survival, and to identify risk factors for the development of significant steatosis and its effect on fibrosis progression. We retrospectively examined 2360 posttransplant biopsies of 548 LT recipients. Survival was compared between patients with significant steatosis and those with grades 0‐1 steatosis. Patients with significant steatosis were compared to controls without steatosis (grade 0) for clinical and laboratory factors and fibrosis progression. Steatosis was found in 309 (56.4%) patients, including 93 (17.0%) patients with significant steatosis. Steatohepatitis (nonalcoholic fatty liver disease activity score ≥ 5) was diagnosed in 57 (10.4%) patients. The prevalence of steatosis increased from 30.3% at 1 year to 47.6% at 10 years after LT ( P 〈 0.001). Survival times did not differ between groups ( P = 0.29). On multivariate analysis of pretransplant factors and initial immunosuppression (IS), alcohol‐induced cirrhosis ( P 〈 0.001) and high body mass index (BMI; P = 0.002) were associated with the development of significant steatosis, whereas increased levels of alkaline phosphatase ( P = 0.01) and mycophenolate mofetil given initially ( P = 0.009) appeared to protect against significant steatosis. On multivariate analysis of posttransplant factors, high BMI ( P 〈 0.001), serum triglycerides ( P 〈 0.001), alcohol consumption ( P = 0.005), and type 2 diabetes mellitus ( P = 0.048) were associated with significant steatosis, whereas high creatinine ( P = 0.02) appeared to protect against significant steatosis. Significant steatosis was not associated with a higher fibrosis stage ( P = 0.62). Posttransplant steatosis affects 56.4% of LT recipients, and the prevalence increases with time after LT. Recipient factors and types of IS affect the risk for significant steatosis, which is not associated with a higher fibrosis stage or worse patient survival. Liver Transplantation 22 644‐655 2016 AASLD.
Type of Medium:
Online Resource
ISSN:
1527-6465
,
1527-6473
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2016
detail.hit.zdb_id:
2002186-0
